Evidence map›Paper›PMID 29328405›Full record

ArticleMolecular medicine reports2018

Liraglutide repairs the infarcted heart: The role of the SIRT1/Parkin/mitophagy pathway.

Huiying Qiao, Haiyan Ren, He Du, Minfang Zhang, Xiaofang Xiong, Rong Lv

RetractedOpen access · hybridAbstract readRetracted Publication
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular medicine reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 53 papers.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
7.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 80 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. NAD in pathological cardiac remodeling: Metabolic regulation and beyond.Biochimica et biophysica acta. Molecular basis of disease · 2024
    Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Regulation of autophagy of the heart in ischemia and reperfusion.Apoptosis : an international journal on programmed cell death · 2023
    Review
  13. Role of mitochondrial DNA in diabetes Mellitus Type I and Type II.Saudi journal of biological sciences · 2022
    Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 1 country.

Huiying QiaoDepartment of Geriatric, Wujiang District No. 1 People's Hospital, Suzhou, Jiangsu 215200, P.R. China.
Haiyan RenCentral Laboratory of Xinjiang Medical University, Urumqi, Xinjiang 830011, P.R. China.
He DuDepartment of Pulmonary Circulation, Shanghai Pulmonary Hospital of Tongji University, Shanghai 200433, P.R. China.
Minfang ZhangDepartment of Pulmonary Circulation, Shanghai Pulmonary Hospital of Tongji University, Shanghai 200433, P.R. China.
Xiaofang XiongDepartment of Cardiovascular Medicine, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei 430000, P.R. China.
Rong LvDepartment of Geriatric, Wujiang District No. 1 People's Hospital, Suzhou, Jiangsu 215200, P.R. China.
Wujiang District People's Hospital · CNHuazhong University of Science and Technology · CNShanghai Pulmonary Hospital · CNTongji University · CNXinjiang Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liraglutide is glucagon‑like peptide‑1 receptor agonist used for treating patients with type 2 diabetes mellitus. The present study aimed to investigate the role and mechanism of liraglutide in repairing the infarcted heart following myocardial infarction. The results of the present study demonstrated that amplification of the dose of liraglutide for ~28 days was able to reduce cardiac fibrosis, inflammatory responses and myocardial death in the post‑infarcted heart. In vitro, liraglutide protected cardiomyocyte mitochondria against the chronic hypoxic damage, inhibiting the mitochondrial apoptosis pathways. Mechanistically, liraglutide elevated the expression of NAD‑dependent protein deacetylase sirtuin‑1 (SIRT1), which increased the expression of Parkin, leading to mitophagy activation. Protective mitophagy reversed cellular adenosine 5'‑triphosphate production, reduced cellular oxidative stress and balanced the redox response, sustaining mitochondrial homeostasis. Notably, following blockade of glucagon‑like peptide 1 receptor or knockdown of Parkin, the beneficial effects of liraglutide on mitochondria disappeared. In conclusion, the results of the present study illustrated the protective role of liraglutide in repairing the infarcted heart via regulation of the SIRT1/Parkin/mitophagy pathway.

Indexed as

Adenosine TriphosphateAnimalsApoptosisCell HypoxiaDisease Models, AnimalLiraglutideMaleMitophagyMyocardial InfarctionMyocardiumMyocytes, CardiacOxidative StressRatsRats, Sprague-DawleyReactive Oxygen SpeciesRNA InterferenceAdenosine TriphosphateLiraglutideparkin proteinReactive Oxygen SpeciesRNA, Small InterferingSirtuin 1Ubiquitin-Protein Ligasesapoptosisinfarcted heartliraglutidemitochondriamitophagyNAD-dependent protein deacetylase sirtuin-1Parkin

Identifiers

PMID29328405
PMCPMC5802177
OpenAlexW2781517806

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.